Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial

NCT ID NCT06068530

Recruiting now Prevention Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether giving entire communities antimalarial drugs along with a malaria vaccine can reduce the spread of the disease better than drugs alone, vaccine alone, or no extra intervention. About 10,000 people aged 6 months and older in malaria-prone villages will take part. The goal is to see if this combined approach lowers malaria cases and infections over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dihydroartemisinin/piperaquine and single low-dose primaquine (antimalarial drugs) plus R21/Matrix-M malaria vaccine
What this could lead to: If successful, this could show that combining mass drug administration with vaccination is a powerful way to reduce malaria transmission and save lives.
What could go wrong: This is a large trial, but results may vary by region and the approach may be logistically challenging. There are also risks of side effects from the drugs or vaccine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMODIUM FALCIPARUM MALARIA

Contacts and locations

Locations

Alikadam Upazila Health Complex
RECRUITING

Bāndarban, 4650, Bangladesh
Lama Upazila Health Complex
RECRUITING

Lāma, 4641, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.